Samsung Biologics Labor Union Warns of Supply Chain Disruptions Amid Governance and ESG Failures
Event summary
- Samsung Biologics Labor Union, representing 75% of the workforce, warns of structural supply chain risks due to unresolved labor disputes.
- Union alleges systemic governance failures, including unfair labor practices and interference from Samsung Electronics' Business Support Office.
- Internal documents leaked in November 2025 reveal evidence of unfair labor practices designed to suppress union activities.
- Union filed criminal complaints against top executives for violations of collective bargaining agreements and labor relations laws.
The big picture
The labor dispute at Samsung Biologics highlights systemic governance failures and ESG risks within the biopharmaceutical contract manufacturing sector. As the world's leading CDMO, Samsung Biologics' ability to resolve these issues will impact its global supply chain reliability and compliance with stringent ESG standards demanded by pharmaceutical clients. The dispute underscores broader industry trends of labor relations challenges and the need for transparent corporate governance in large conglomerates.
What we're watching
- Governance Dynamics
- Whether Samsung Biologics can break free from Samsung Electronics' structural control to resolve labor disputes autonomously.
- Supply Chain Impact
- How potential strikes will affect the uninterrupted 24/7 continuous manufacturing required in the biopharmaceutical industry.
- ESG Compliance
- The pace at which Samsung Biologics addresses ESG risks to meet the standards demanded by global pharmaceutical clients.
Our editorial coverage: